To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
Europe | European ＆ international partnerships | Brain | Diseases
Autism Innovative Medicine Studies – 2 – Trials
AIMS-2-TRIALS, a continuation of the EU-AIMS project and the first European network of clinical trials for autism, aims to improve and personalize treatments for people with Autism Spectrum Disorders (precision medicine).
Autism spectrum disorders (ASD) affect around 1 % of the population and are characterised by difficulties in social interactions and communication as well as repetitive behaviours. The precise symptoms and their severity vary widely from one person to another; some are only mildly afflicted and can lead relatively independent lives, while others are severely disabled and require a lot of specialist care. People with ASD often have other conditions, including epilepsy, depression, anxiety and attention deficit hyperactivity disorder (ADHD). Today, there are no drugs designed specifically to treat ASD; instead, those affected are treated with medicines designed for other conditions.By creating the first European clinical trial network for autism, AIMS-2-TRIALS aims to improve and personalize treatments for people with ASD (precision medicine). It will do this by creating a pipeline for the development, testing and implementation of new treatments with stakeholder involvement at every stage. The project will establish a global network of clinical trials to validate biological markers and endpoints and reliably show whether a treatment is effective and appropriate. As part of this project coordinated by King's College, the CEA team will conduct genetic imaging studies.
AIMS-2-TRIAL is a continuation of the EU-AIMS project (2012-2018).
Joliot Institute Contact: Vincent Frouin (firstname.lastname@example.org)
ABOUT IMI - INNOVATIVE MEDICINES INITIATIVE
IMI is the world's largest public-private partnership (PPP) in the life sciences. It is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations).
The objective of IMI, particularly in its second phase (IMI2, 2014-2020), is to develop new generation vaccines, drugs and treatments, such as new antibiotics.
For more information: https://www.imi.europa.eu/
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.